{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:24:59Z","timestamp":1770229499731,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.carrev.2023.12.011","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T17:58:19Z","timestamp":1703181499000},"page":"73-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and efficacy of clot-dissolving therapies for submassive pulmonary embolism: A network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"62","author":[{"given":"Hussam","family":"Al Hennawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Khuzzaim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Talal","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Affan","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lein","family":"Mathbout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aalaa","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Mathbout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Klugherz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.carrev.2023.12.011_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.suc.2017.11.001","article-title":"Evidence-based therapies for pharmacologic prevention and treatment of acute deep vein thrombosis and pulmonary embolism","volume":"98","author":"Jacobs","year":"2018","journal-title":"Surg Clin North Am"},{"issue":"9","key":"10.1016\/j.carrev.2023.12.011_bb0010","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","article-title":"Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany","volume":"41","author":"Keller","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.carrev.2023.12.011_bb0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/1570161120666220811155353","article-title":"Comparison of efficacy and safety between thrombolysis plus anticoagulation vs. anticoagulation alone for the treatment of acute submassive pulmonary embolism: a systematic review and meta-analysis","volume":"20","author":"Pan","year":"2022","journal-title":"Curr Vasc Pharmacol"},{"issue":"10","key":"10.1016\/j.carrev.2023.12.011_bb0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurheartj\/ehu218","article-title":"Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis","volume":"36","author":"Marti","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.carrev.2023.12.011_bb0035","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.4187\/respcare.03197","article-title":"Thrombolysis versus anticoagulation for the initial treatment of moderate pulmonary embolism: a meta-analysis of randomized controlled trials","volume":"59","author":"Chen","year":"2014","journal-title":"Respir Care"},{"issue":"23","key":"10.1016\/j.carrev.2023.12.011_bb0040","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.carrev.2023.12.011_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jvir.2019.02.024","article-title":"Nationwide trends in use of catheter-directed therapy for treatment of pulmonary embolism in Medicare beneficiaries from 2004 to 2016","volume":"30","author":"Gayou","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"20","key":"10.1016\/j.carrev.2023.12.011_bb0050","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1161\/CIR.0000000000000707","article-title":"Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association","volume":"140","author":"Giri","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jvsv.2017.12.058","article-title":"Catheter-directed interventions compared with systemic thrombolysis achieve improved ventricular function recovery at a potentially lower complication rate for acute pulmonary embolism","volume":"6","author":"Avgerinos","year":"2018","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jvsv.2018.03.010","article-title":"A meta-analysis of outcomes of catheter-directed thrombolysis for high- and intermediate-risk pulmonary embolism","volume":"6","author":"Avgerinos","year":"2018","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.113.005544","article-title":"Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism","volume":"129","author":"Kucher","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.carrev.2023.12.011_bb0075","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcin.2021.04.049","article-title":"Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism","volume":"14","author":"Avgerinos","year":"2021","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.carrev.2023.12.011_bb0080","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.carrev.2023.12.011_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0090","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.carrev.2023.12.011_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.carrev.2023.12.011_bb0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Mak"},{"issue":"6","key":"10.1016\/j.carrev.2023.12.011_bb0105","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.98.6.1473","article-title":"A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism","volume":"98","author":"Levine","year":"1990","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.carrev.2023.12.011_bb0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.0954-6820.1978.tb14909.x","article-title":"A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism","volume":"203","author":"Ly","year":"1978","journal-title":"Acta Med Scand"},{"issue":"8844","key":"10.1016\/j.carrev.2023.12.011_bb0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0140-6736(93)90274-K","article-title":"Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion","volume":"341","author":"Goldhaber","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.carrev.2023.12.011_bb0120","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.thromres.2009.09.017","article-title":"Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism","volume":"125","author":"Becattini","year":"2010","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.carrev.2023.12.011_bb0125","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.15537\/smj.2018.11.22717","article-title":"Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism","volume":"39","author":"Zhang","year":"2018","journal-title":"Saudi Med J"},{"issue":"5904","key":"10.1016\/j.carrev.2023.12.011_bb0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.1.5904.343","article-title":"Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism","volume":"1","author":"Tibbutt","year":"1974","journal-title":"Br Med J"},{"issue":"15","key":"10.1016\/j.carrev.2023.12.011_bb0135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM198010093031502","article-title":"Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism","volume":"303","author":"Sharma","year":"1980","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.carrev.2023.12.011_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ehj.2011.09.006","article-title":"Efficacy and safety of high dose versus low dose streptokinase for treatment of submassive pulmonary embolism","volume":"63","author":"Abdelsamad","year":"2011","journal-title":"Egypt Heart J"},{"issue":"2","key":"10.1016\/j.carrev.2023.12.011_bb0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.14740\/jocmr2829w","article-title":"Efficacy and safety of thrombolytic therapy in acute submassive pulmonary embolism: follow-up study","volume":"9","author":"Sinha","year":"2017","journal-title":"J Clin Med Res"},{"issue":"15","key":"10.1016\/j.carrev.2023.12.011_bb0150","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.carrev.2023.12.011_bb0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000195517","article-title":"Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial","volume":"54","author":"Marini","year":"1988","journal-title":"Respiration"},{"issue":"15","key":"10.1016\/j.carrev.2023.12.011_bb0160","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa021274","article-title":"Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism","volume":"347","author":"Konstantinides","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.carrev.2023.12.011_bb0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"\u201cMOPETT\u201d Investigators. Moderate pulmonary embolism treated with thrombolysis (from the \u201cMOPETT\u201d Trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.carrev.2023.12.011_bb0170","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0735-1097(92)90002-5","article-title":"PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2","volume":"20","author":"Dalla-Volta","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.carrev.2023.12.011_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MAJ.0b013e3181f1fc3e","article-title":"Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin","volume":"341","author":"Fasullo","year":"2011","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.carrev.2023.12.011_bb0180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/153857447901300107","article-title":"Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison","volume":"13","author":"Dotter","year":"1979","journal-title":"Vasc Surg"},{"key":"10.1016\/j.carrev.2023.12.011_bb0185","doi-asserted-by":"crossref","unstructured":"Jerjes-Sanchez C, Ram\u00edrez-Rivera A, de Lourdes Garc\u00eda M null, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995;2(3):227\u2013229. doi:https:\/\/doi.org\/10.1007\/BF01062714.","DOI":"10.1007\/BF01062714"},{"key":"10.1016\/j.carrev.2023.12.011_bb0190","article-title":"Thrombolytic therapy for pulmonary embolism","volume":"2021(4):CD004437","author":"Zuo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.carrev.2023.12.011_bb0195","first-page":"104","article-title":"Thrombolytic-plus-anticoagulant therapy versus anticoagulant-alone therapy in submassive pulmonary thromboembolism (TVASPE study): a randomized clinical trial","volume":"9","author":"Taherkhani","year":"2014","journal-title":"J Tehran Heart Cent"},{"issue":"3","key":"10.1016\/j.carrev.2023.12.011_bb0200","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.97.3.528","article-title":"Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators","volume":"97","year":"1990","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.carrev.2023.12.011_bb0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jth.12521","article-title":"Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial","volume":"12","author":"Kline","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.carrev.2023.12.011_bb0210","first-page":"E501","article-title":"Efficacy and safety of catheter-directed thrombolysis versus standard anticoagulation for the treatment of intermediate-risk acute pulmonary embolism: a systematic review and meta-analysis","volume":"195","author":"Planer","year":"2023","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.carrev.2023.12.011_bb0215","first-page":"1234","article-title":"Systemic thrombolysis, catheter-directed thrombolysis and anticoagulation for intermediate-high risk acute pulmonary embolism: a network meta-analysis of randomized controlled trials","volume":"11","author":"Mathew","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.carrev.2023.12.011_bb0220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.0000137826.09715.9C","article-title":"Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials","volume":"110","author":"Wan","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.carrev.2023.12.011_bb0225","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1378\/chest.09-0765","article-title":"Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial","volume":"137","author":"Wang","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.carrev.2023.12.011_bb0230","first-page":"813","article-title":"Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review","volume":"43","author":"Engelberger","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.carrev.2023.12.011_bb0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2022.05.011","article-title":"Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study","volume":"251","author":"Klok","year":"2022","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.carrev.2023.12.011_bb0240","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1055\/a-1653-4699","article-title":"Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial","volume":"122","author":"Sanchez","year":"2022","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.carrev.2023.12.011_bb0245","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jamacardio.2022.3591","article-title":"Catheter-directed thrombolysis vs anticoagulation in patients with acute intermediate-high-risk pulmonary embolism: the CANARY randomized clinical trial","volume":"7","author":"Sadeghipour","year":"2022","journal-title":"JAMA Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838923009429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838923009429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:40:28Z","timestamp":1715362828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838923009429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":48,"alternative-id":["S1553838923009429"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2023.12.011","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of clot-dissolving therapies for submassive pulmonary embolism: A network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2023.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}